Liver transplantation is often used to treat patients with end-stage liver disease as a result of infection with HCV. However, the optimal choice of immunosuppressants in these patients is still undecided. In this article Luc van der Laan and colleagues explore the effect of different immunosuppressants on the complex cellular events involved in HCV infection and interferon signalling.
- Qiuwei Pan
- Hugo W. Tilanus
- Luc J. W. van der Laan
